IndicationsSelumetinib is a kinase inhibitor indicated for the treatment of pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN).Dosage and Administration
- The recommended dose is 25 mg/m² orally twice daily on an empty stomach. Do not eat for 2 hours before or 1 hour after each dose.
- For patients with moderate hepatic impairment (Child-Pugh B), reduce the dose to 20 mg/m² orally twice daily.
- The recommended dose for patients with severe hepatic impairment (Child-Pugh C) has not been established.
Specification
25 mg per capsule, 60 capsules per box.
Reviews
There are no reviews yet.